18 results about "Gp41" patented technology

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

The present invention provides a multispecific anti-HIV antibody that binds to multiple epitopes on HIV envelope protein, wherein the antibody comprises:i. an amino acid sequence that binds to a V1 / V2 apex glycan epitope;ii. an amino acid sequence that binds to a V3-base glycan region epitope;iii. an amino acid sequence that binds to a CD4 binding site (CD4bs) epitope;iv. an amino acid sequence that binds to a gp120 / gp41 interface epitope; andv. an amino acid sequence that binds to a membrane proximal external region (MPER) epitope.

The present application belongs to the field of biomedical detection technology, and particularly relates to a kit for detecting human immunodeficiency virus antibodies and hepatitis E virus antigens in urine based on a latex method, and a test strip for detecting human immunodeficiency virus antibodies and hepatitis E virus antigens in urine based on a latex method. The test strip comprises a base plate, a sample pad, a latex pad, a nitrocellulose membrane and a water absorption pad. The sample pad, the latex pad, the nitrocellulose membrane and the water absorption pad are sequentially and adjacently bonded on the base plate in a chromatographic direction. The nitrocellulose membrane is provided with a quality control line and two detection lines. The quality control line is coated with goat anti-mouse IgG. The two detection lines are respectively coated with streptavidin and HEV monoclonal antibody 2. The latex pad is coated with latex-labeled GP41, GP36, GP120 mixed antigen, GP160 antigen and HEV monoclonal antibody 1. The sample pad is coated with biotin-coupled SPA. The kit disclosed by the present application is convenient to use, simple to operate, and can simultaneously detect HIV antibodies and HEV antigens.

This application discloses an HIV antigen comprising the gp41 protein; said gp41 protein contains at least one amino acid residue selected from the following: T at position 85; K at position 98; a basic amino acid R or K at position 109; a neutral amino acid L or I at position 111; a basic amino acid K or R at position 132; N at position 133; and an acidic amino acid D or E at position 139. The HIV antigen of this application has the advantages of high specificity and high sensitivity.

The present disclosure relates to vaccine compositions against respiratory syncytial virus (RSV) that are tomato-based and their methods of production. The vaccine compositions comprise tomato fruit and plant-expressed fragment of RSV F protein, preferably the ectodomain of the RSV F protein. In some aspects, the vaccine compositions comprise tomato fruit and plant-expressed human immunodeficiency virus (HIV) virus-like particle (VLP) wherein the fragment of RSV F protein is displayed on the VLP surface. For example, the vaccine compositions are tomato paste spiked with the plant-expressed HIV VLP. In certain embodiments, the plant-expressed HIV VLP comprises a Gag protein; a fragment of gp41 protein, which comprises the C-terminal cytosolic domain of the gp41 protein; and a fragment of RSV F protein, wherein the fragment of RSV F protein lacks the p27 region and the C-terminus of the fragment of RSV F protein is linked to the N-terminus of the fragment of gp41 protein.

The present application relates to a kind of multispecific and / or multivalent binding protein for preventing and / or treating HIV infection, it includes at least 3 antigen binding sites, part of antigen binding site is specifically bound HIV-1-gp41 or HIV-1-gp120 or HIV-1-gp160, still part of antigen binding site is specifically bound human CD4 receptor or human CCR5 receptor;The binding protein of the present application has excellent broad-spectrum neutralizing ability in the treatment or prevention of HIV infection, provides a new solution for the problem of drug resistance escape caused by HIV virus variation, in addition, the present application inventor also unexpectedly found that the binding protein of the present application can treat or prevent the tumor-related disease caused by HIV infection.

The HIV-1 envelope glycoprotein (Env) is the sole neutralizing determinant on the viral surface. The Env gpl20 and gp41 subunits mediate receptor binding and membrane fusion. HIV- 1 neutralizing antibodies can be generated following immunization via expressing membrane-bound Env anchored on the cell-surface genetically using the natural HIV gp41 transmembrane (TM) spanning domain. Inventors used "native flexibly linked" (NFL) stabilized soluble trimers that are both near-native in conformation and cleavage-independent. The NFL construct was genetically fused to the HIV TM domain using a short linker or restoring the native membrane external proximal region to express the full HIV Env ectodomain on the plasma membrane. Both forms of cell-surface NFL trimers, without and with the MPER, displayed favorable antigenic profiles when expressed from plasmid DNA or mRNA. Inoculation of rabbits with mRNA lipid nanoparticles (LNP) expressing membrane-bound stabilized HIV Env NFL trimers generated tier 2 neutralizing antibody serum titers in immunized animals.

The invention discloses an enzyme-labeled antigen for HIV diagnosis, the enzyme-labeled antigen is obtained by carrying out a directional coupling reaction on a gp41 recombinant antigen and an enzyme, the sequence of the gp41 recombinant antigen is shown as SEQ ID NO: 1, the enzyme is alkaline phosphatase, and the gp41 recombinant antigen and the enzyme are separated from each other. The preparation method of the enzyme-labeled antigen comprises the following steps: genetic engineering expression and purification of the antigen, modification of the antigen, activation of alkaline phosphatase, directional coupling reaction and stability optimization. The HIV recombinant antigen-alkaline phosphatase marker prepared by the invention is high in activity, strong in specificity, good in stability and good in inter-batch uniformity.

To provide a multispecific antigen-binding molecule targeting HIV and a method for its use. [Solution] A multispecific antigen-binding molecule is provided, comprising a bispecific antibody that binds to CD3 containing the HIV envelope protein gp120 and to the HIV antigen. Methods of using such an antigen-binding molecule to treat or prevent HIV infection are also provided. In some embodiments, the multispecific or bispecific molecule comprises a first antigen-binding domain targeting human CD3, which is a single-chain variable fragment (scFv) fused to Fc, while a second antigen-binding domain targeting the HIV antigen (e.g., gp120 or gp41) consists of a Fab antigen-binding fragment fused to Fc.

The invention discloses an HIV (Human Immunodeficiency Virus) resistant molecule and application thereof. The amino acid sequence of the HIV resistant molecule comprises a segment A and a segment B from the N terminal to the C terminal; the section A is a membrane fusion inhibition polypeptide 2P23 aiming at an HIV gp41 structural domain induced membrane fusion process; the segment B is GPI signal peptide of BST2, and the amino acid sequence is shown as SEQ ID NO: 4. The HIV resistant molecule disclosed by the invention comprises GPI signal peptide of virus membrane fusion inhibition polypeptide 2P23 and BST2, and functions of broad-spectrum inhibition of HIV from entering cells and being copied in the cells are played through the two functional areas. The multifunctional HIV resistant cell disclosed by the invention is designed aiming at the mechanism of HIV extracellular invasion and intracellular replication, and has strong and broad-spectrum antiviral activity, so that the aims of improving the curative effect and reducing virus escape are fulfilled, and a new thought is provided for HIV treatment.

The invention relates to novel HIV gp41 antigen compositions that are suitable for detecting antibodies against HIV in an isolated biological sample providing high specificity immunoassay results. It further relates to methods detecting HIV antibodies, use of novel HIV gp41 antigen compositions in immunoassays as well as to reagent kits comprising novel HIV gp41 antigen compositions.

Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins of the V1 / V2 apex region of glycoprotein 120 (gp120) or the gp120-gp41 interface region of gp120 and gp41 as well as having a CD4 domain that binds to the CD4bs of gp120.

The present invention provides a preparation method, reagent strip and reagent pen for detecting HIV (1+2) antibodies in urine, the method comprising: preparing a PET film and a nitrocellulose membrane; the PET film is coated with mouse anti-human IgG and R-IgG labeled with colored latex microspheres, the nitrocellulose membrane is coated with gp41 antigen and gp36 antigen for detecting HIV type 1 antibodies and HIV type 2 antibodies, and goat anti-rabbit IgG for quality control; the PET film, the nitrocellulose membrane and blotting paper are sequentially pasted on a base plate, the PET film, the nitrocellulose membrane and the blotting paper overlapping each other for a preset length, to obtain the HIV (1+2) antibody reagent strip for detecting urine. The HIV (1+2) antibody detection preliminary screening reagent strip prepared by the method of the present invention has higher detection sensitivity, lower cost and more convenient operation.

The application discloses a kit for detecting human immunodeficiency virus P24 antigen and antibodies based on a latex method and a preparation method thereof, a test strip for detecting human immunodeficiency virus P24 antigen and antibodies based on a latex method, and the test strip comprises a bottom plate, a sample pad, a latex pad, a nitrocellulose membrane and a water absorption pad, the sample pad, the latex pad, the nitrocellulose membrane and the water absorption pad are sequentially and adjacently bonded on the bottom plate in a chromatographic direction, the nitrocellulose membrane is coated with one quality control line and three detection lines, the quality control line is coated with goat anti-mouse IgG, and the three detection lines are respectively coated with GP36 antigen, GP41 antigen and P24 monoclonal antibody 2; the latex pad is coated with latex-labeled GP41, GP36, GP120 mixed antigen and P24 monoclonal antibody 1; and the human immunodeficiency virus P24 antigen and antibody detection test strip provided by the application can realize simultaneous detection of HIV antibodies and P24 antigen for one sample, and can distinguish whether the HIV antibodies are type 1 or type 2.

System for detecting interactions between a first a second protein comprising: (a) a first construct comprising the first protein fused to a first handle comprising a β10 peptide or a β9 peptide of a nanoluciferase fused to the N-terminal of a modified N-terminus intein (IN) of GP41-1; and (b) a second construct comprising the second protein fused to a second handle comprising a modified C-terminus intein (IC) of GP41-1 fused at its C-terminal to a β9 peptide when the β10 is fused to the modified IN, or to the β10 peptide when the β9 peptide is fused to the modified IN. Interaction between the first and second proteins reconstitutes the IN and IC into the GP41-1 that induces splicing of the reconstituted GP41-1 from the first handle and the second handle, ligating the first and the second proteins and arranging the β10 peptide and β9 peptide in a fused tandem.

The application provides an HIV gp41 polypeptide mutant and application thereof, and relates to the technical field of biology.The amino acid sequence of the HIV gp41 polypeptide mutant comprises the amino acid sequence of the HIV gp41 polypeptide in which the 122th and / or 124th amino acid is a non-charged amino acid.The HIV gp41 polypeptide mutant has improved sensitivity and specificity in detecting HIV-1 antibodies in a sample, and improves the accuracy of HIV antibody detection.

The present application relates to a bifunctional fusion protein targeting CCR5 and gp41 and its application in the preparation of anti-human immunodeficiency virus drugs, and belongs to the technical field of biological medicine. The present application provides a bifunctional fusion protein targeting CCR5 and gp41, wherein the bifunctional fusion protein comprises: a fusion protein obtained by connecting a polypeptide 2P23 to the N terminus and / or C terminus of the light chain and / or heavy chain of an antibody PRO 140 or a PRO 140 mutant through a connecting peptide; or a fusion protein obtained by connecting a tag to the N terminus and / or C terminus of the above-mentioned fusion protein. The novel bifunctional fusion protein constructed in the present application not only overcomes the limitation that the original PRO 140 antibody is invalid for CXCR4 tropic strains, but also significantly improves the inhibitory activity and broad spectrum for CCR5 tropic strains, and has a higher drug resistance barrier.

This invention belongs to the fields of molecular biology and in vitro diagnostics, specifically relating to a method and kit for multiplex isothermal nucleic acid amplification based on a Gp41-Gp59 ​​fusion helicase protein and a UvsX-UvsY recombinant system. The method includes: providing an engineered helicase fusion protein comprising a Gp41 hexamer helicase domain derived from bacteriophage T4 and a Gp59 loading factor domain derived from bacteriophage T4, covalently linked by a (GGGGS)n linker sequence; providing a recombinase engine comprising a UvsX recombinase and a UvsY loading factor; running the helicase engine and recombinase engine in parallel in the same reaction system to amplify template nucleic acid under isothermal conditions of 37-45°C; and providing a kit containing the above components. This invention achieves synergistic amplification using a dual-engine system, offering advantages such as high sensitivity, ability to amplify long fragments, and support for multiplex detection.